GIP receptor raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-19 and is reviewed periodically as new material appears.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Unmodified peptide backbone |
| Molecular mass | approx. 4,813 Da | 39-residue linear chain |
| Receptor targets | GIP and GLP-1 | Dual agonist activity |
| Route | Subcutaneous injection | Weekly administration interval |
| Elimination half-life | approx. 5 days | Supports weekly dosing schedule |
脂肪酸侧链的存在使该肽与血浆白蛋白结合能力增强，从而延长循环半衰期，支持每周一次给药的用药间隔。白蛋白结合同时改变组织分布特征，减慢肾脏清除速度。该设计思路在多种长效肽类药物中被反复采用，属于既定的药代动力学策略。
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
Tirzepatide is a synthetic peptide built from 39 amino acid residues. Its sequence is related to human glucose-dependent insulinotropic polypeptide, with modifications that include a C-terminal extension and a C20 fatty diacid joined through a linker. Those changes raise the molecule's affinity for serum albumin, which slows renal filtration and lengthens the time it stays in circulation. The free base has an average molecular mass near 4813.5 daltons. The compound is made by solid-phase peptide synthesis followed by chromatographic purification.
At the receptor level, tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. Both belong to the class B family of G protein-coupled receptors and signal largely through cyclic AMP accumulation. The compound binds the two receptors with differing affinity, and the pattern of signaling at each site is described in the literature as biased rather than simply proportional to occupancy. Tissues carrying these receptors include pancreatic islets, adipose tissue, the central nervous system, and the gastrointestinal tract. The relative weight of each receptor population in producing metabolic effects continues to be studied.
Published work supports the view that engaging two incretin receptors produces changes in glucose handling and body weight larger than those seen with single-receptor activation. Why that difference arises is not fully settled. Open questions include how much of the observed weight effect depends on central versus peripheral signaling, and whether the two receptors form interacting complexes. Most reported findings come from controlled trials and animal models, and translation between species is imperfect. Further research is expected to refine these points over time.
Concerns expressed by some politicians on the subject of salvia reflect those of the media, with comparisons to LSD and particular focus on "protecting our children" being echoed; and with legislative proposals following soon after news stories breaking. Some arguments against salvia have been of a preventative nature, "We need to stop this before it gets to be a huge problem not after it gets to be a huge problem," or of an imitative nature, "The Australians have clearly found a problem with it. There's obviously a risk in people taking it." Concerns about driving while under the influence of salvia have also been expressed. Opponents of more prohibitive measures against salvia argue that such reactions are largely due to an inherent prejudice and a particular cultural bias rather than any actual balance of evidence, pointing out inconsistencies in attitudes toward other more toxic and addictive drugs such as alcohol and nicotine. While not objecting to some form of legal control, in particular with regard to the sale to minors or sale of enhanced high-strength extracts, most salvia proponents otherwise argue against stricter legislation. Those advocating consideration of Salvia divinorum's potential for beneficial use in a modern context argue that more could be learned from Mazatec culture, where salvia is not really associated with notions of drug taking at all and it is rather considered as a spiritual sacrament. In light of this it is argued that Salvia divinorum could be better understood more positively as an entheogen rather than pejoratively as a hallucinogen.
==== Electrospinning ==== Electrospinning is a highly versatile technique that can be used to produce continuous fibers ranging in diameter from a few microns to a few nanometers. In a typical electrospinning set-up, the desired scaffold material is dissolved within a solvent and placed within a syringe. This solution is fed through a needle and a high voltage is applied to the tip and to a conductive collection surface. The buildup of electrostatic forces within the solution causes it to eject a thin fibrous stream towards the oppositely charged or grounded collection surface. During this process the solvent evaporates, leaving solid fibers leaving a highly porous network. This technique is highly tunable, with variation to solvent, voltage, working distance (distance from the needle to collection surface), flow rate of solution, solute concentration, and collection surface. This allows for precise control of fiber morphology. On a commercial level however, due to scalability reasons, there are 40 or sometimes 96 needles involved operating at once. The bottle-necks in such set-ups are: 1) Maintaining the aforementioned variables uniformly for all of the needles and 2) formation of "beads" in single fibers that we as engineers, want to be of a uniform diameter. By modifying variables such as the distance to collector, magnitude of applied voltage, or solution flow rate – researchers can dramatically change the overall scaffold architecture.
Interest in the collective's work gave rise to an artistic movement referred to as the Rogue Taxidermy art movement, or alternately, the Taxidermy Art movement. Apart from describing a genre of fine art, the term "rogue taxidermy" has expanded in recent years and has also become an adjective applied to unorthodox forms of traditional taxidermy such as anthropomorphic mounts and composite mounts where two or more animals are spliced together. (e.g.; sideshow gaffs of conjoined "freak" animals and mounts of jackalopes or other fictional creatures) In addition to being the impetus for the art movement, the inception of the genre also marked a resurgence of interest in conventional (traditional) forms of taxidermy.
Sources: en.wikipedia.org
=== Cardiovascular diseases === In the 1930s, polyphenols (then called vitamin P) were considered as a factor in capillary permeability, followed by various studies through the 21st century of a possible effect on cardiovascular diseases. For most polyphenols, there is no evidence for an effect on cardiovascular regulation, although there are some reviews showing a minor effect of consuming polyphenols, such as chlorogenic acid or flavan-3-ols, on blood pressure.
Affectional bond: define relationships in which neither partner is limerent. Limerent–Nonlimerent bond: define relationships in which one partner is limerent. Limerent–Limerent bond: define relationships in which both partners are limerent. The constitution of these bonds may vary over the course of the relationship, in ways that may either increase or decrease the intensity of the limerence. A characteristic of this delineation made by Tennov, is that based on her research and interviews with over 500 people, all human bonded relationships can be divided into three varieties being defined by the amount of limerence or non-limerence each partner contributes to the relationship.
On March 10, Judge Ali ruled that the Trump administration must pay for projects completed by February 13 at the rate of 300 back payments a day, meaning four days for all 1,200 back payments. On March 11, ABC News reported that, until recently, no payments were being made because DOGE had disabled the payment system. On March 20, Reuters reported that the Trump administration is close to paying the $671 million owed to the organizations which sued.
=== Selected overdoses === A mysterious woman, known as the Isdal Woman, was found dead in Bergen, Norway, on 29 November 1970. Her death was caused by some combination of burns, phenobarbital, and carbon monoxide poisoning; many theories about her death have been posited, and it is believed that she may have been a spy. British veterinarian Donald Sinclair, the inspiration for the character Siegfried Farnon in the All Creatures Great and Small book series by James Herriot, committed suicide at the age of 84 by injecting himself with an overdose of phenobarbital. Activist Abbie Hoffman also committed suicide by consuming phenobarbital, combined with alcohol, on 12 April 1989; the residue of around 150 pills was found in his body at autopsy. Thirty-nine members of the Heaven's Gate UFO cult committed mass suicide in March 1997 by drinking a lethal dose of phenobarbital and vodka "and then lay down to die" hoping to enter an alien spacecraft.
Sources: en.wikipedia.org
==== Refeeding syndrome ==== When a malnourished person is refed too quickly, they may develop refeeding syndrome (RFS), which can be life-threatening. Factors associated with increased risk for RFS include:
Elsewhere, the PAF carried out airstrikes in parts of Khost, Kandahar provinces, and Kabul. Taliban-led Afghan government deputy spokesperson Hamdullah Fitrat said that 52 people had been killed and 66 others injured as a result of Pakistani attacks on the provinces of Paktika, Khost, Kunar, Nangarhar, and Kandahar. The Taliban-led Afghan Ministry of Defense said that 110 Pakistani soldiers had been killed and 27 Pakistani border posts had been captured. The ministry also said that it had attacked Pakistani military sites in Miranshah and Spinwam, though Pakistani officials denied that any such attack had taken place. On the same day, an attack by Pakistani Taliban on Sra Khawra police checkpost in Khyber Pakhtunkhwa injured one policeman and 6 civilians. Separately, Pakistani officials said that 352 Afghan Taliban members had been killed and more than 535 wounded since the fighting began. They added that Pakistani forces had destroyed 130 Taliban border posts, captured 26 others, and destroyed 171 tanks and armoured personnel carriers belonging to Afghan Taliban forces. The officials also said that the PAF had targeted 41 locations in Afghanistan, including brigade and battalion headquarters in Nangarhar province and an army headquarters in Kandahar province. Later on the day, clashes resumed between Pakistan border guards and Afghan Taliban forces along the border areas of Nangarhar, Khost, and Paktia provinces. Taliban-led Afghan armed forces' 203rd Mansouri Corps in Paktia released a video depicting fresh forces being dispatched to areas near the border.
During sexual arousal, the clitoris and the rest of the vulva engorge and change color as the erectile tissues fill with blood (vasocongestion), and the individual experiences vaginal contractions. The ischiocavernosus and bulbocavernosus muscles, which insert into the corpora cavernosa, contract and compress the dorsal vein of the clitoris (the only vein that drains the blood from the spaces in the corpora cavernosa), and the arterial blood continues a steady flow and having no way to drain out, fills the venous spaces until they become turgid and engorged with blood. This is what leads to clitoral erection. The prepuce has retracted and the glans becomes more visible. The glans doubles in diameter upon arousal and further stimulation becomes less visible as it is covered by the swelling of the clitoral hood. The swelling protects the glans from direct contact, as direct contact at this stage can be more irritating than pleasurable. Vasocongestion eventually triggers a muscular reflex, which expels the blood that was trapped in surrounding tissues, and leads to an orgasm. A short time after stimulation has stopped, especially if orgasm has been achieved, the glans becomes visible again and returns to its normal state, with a few seconds (usually 5–10) to return to its normal position and 5–10 minutes to return to its original size. If orgasm is not achieved, the clitoris may remain engorged for a few hours, which women often find uncomfortable. Additionally, the clitoris is very sensitive after orgasm, making further stimulation initially painful for some women.
Sources: en.wikipedia.org
It is a dual GIP and GLP-1 receptor agonist, frequently grouped with incretin-based peptide therapeutics. It is a peptide rather than a small molecule and is given by subcutaneous injection.
Selective agents engage only the GLP-1 receptor, whereas tirzepatide activates GIP and GLP-1 receptors simultaneously. This difference in receptor coverage is the principal pharmacological distinction emphasised in comparative reviews.
Downstream signalling is partly characterised, but the quantitative contribution of GIP versus GLP-1 receptor activation to metabolic outcomes is not settled. Review articles commonly flag this as an unresolved question rather than a settled finding.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.